CALL 1-866-ZEMAIRA
(1-866-936-2472) Stay
Connected

Important Safety
Information Prescribing
Information For Healthcare
Professionals

About Alpha-1
Why ZEMAIRA?
Patient Stories
Treatment Support
Helpful Resources

About Alpha-1
Why ZEMAIRA?
Patient Stories
Treatment Support
Helpful Resources
For Healthcare
Professionals
Facebook
About CSL Behring

Prescribing Information

Download Prescribing Information

Important Safety Information

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), ZEMAIRA^® is indicated to raise the plasma level of alpha₁-proteinase inhibitor (A₁-PI) in patients with A₁-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

ZEMAIRA may not be suitable for everyone; for example, people with known hypersensitivity to components used to make ZEMAIRA, those with a history of anaphylaxis or severe systemic response to A₁-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to ZEMAIRA include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving ZEMAIRA: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because ZEMAIRA is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

Please see full prescribing information for ZEMAIRA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

Important Safety Information | Prescribing Information | Contact Us | Site Map | Privacy Policy | Cookie Policy | Terms of Use | About CSL Behring | Patent Information | COVID-19 Updates

ZEMAIRA is manufactured and distributed by CSL Behring LLC.
ZEMAIRA® is registered trademark of CSL Behring LLC.
ZEMAIRA Connect^SM is a service mark of CSL Behring LLC.
ZEMAIRA® Signature Savings^SM and CSL Behring Assurance^SM are service marks of CSL Behring LLC.
DNA₁ Advanced Alpha-1 Screening™ is a trademark of CSL Behring LLC.

© 2024 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR-0364-MAR22

You are now leaving the current website.

Do you want to continue?

NO

YES